Table 2.
Clinical outcomes across the most recent published studies
| Year published | Patients | Valve | Access | Procedural success (%) | 30-d mortality (%) | 1-yr mortality (%) | |
| PARTNER EU[55] | 2010 | 61 | ES | TF | 91 | 8.1 | 21.3 |
| SOURCE Registry[56] | 2010 | 463 | ES | TF | 95.2 | 6.3 | - |
| PARTNER cohort B[11] | 2010 | 179 | ES | TF | - | 5 | 30.7 |
| Rodés-Cabau et al[24] | 2010 | 168 | ES | TF | 90.5 | 9.5 | 25 |
| PARTNER cohort A[12] | 2011 | 244 | ES | TF | - | 3.3 | 22.2 |
| PARTNER EU[55] | 2010 | 69 | ES | TA | 91 | 18.8 | 51.7 |
| SOURCE Registry[56] | 2010 | 575 | ES | TA | 92.7 | 10.3 | - |
| Rodés-Cabau et al[24]1 | 2010 | 177 | ES | TA | 96.1 | 11.3 | 23 |
| Wong et al[45]1 | 2010 | 60 | ES | TA | 98.3 | 18.3 | - |
| PARTNER cohort A[12] | 2011 | 104 | ES | TA | - | 3.8 | 29 |
| Grube et al[43] | 2008 | 1022 | CS | TF | 91.2 | 10.8 | - |
| Piazza et al[57] | 2008 | 646 | CS | TF | 97.2 | 8 | - |
| Avanzas et al[58] | 2010 | 108 | CS | 103 TF/5 TS | 98.1 | 7.4 | 17.7 |
| Tamburino et al[27] | 2011 | 663 | CS | 599 TF/64 TS | 98 | 5.4 | 15 |
1
Dr. Wong and Dr. Rodés-Cabau are from the same centre, probably patients overlapped in these two studies;
2
Results referred to the third generation Corevalve ReValving System (CS) device only. ES: Edwards SAPIEN; TF: Transfemoral; TA: Transapical; TS: Trans-subclavian.